Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - hydrocortisone 20mg;   - tablet - 20 mg - active: hydrocortisone 20mg   excipient: lactose monohydrate magnesium stearate maize starch povidone purified talc

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - hydrocortisone 5mg;   - tablet - 5 mg - active: hydrocortisone 5mg   excipient: lactose monohydrate magnesium stearate maize starch povidone purified talc

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin sodium 1000mg;   - powder for injection - 1000 mg - active: amoxicillin sodium 1000mg   - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin sodium 250mg;   - powder for injection - 250 mg - active: amoxicillin sodium 250mg   - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin sodium 500mg;   - powder for injection - 500 mg - active: amoxicillin sodium 500mg   - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - aciclovir 400mg;   - dispersible tablet - 400 mg - active: aciclovir 400mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water sodium starch glycolate - · treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. · suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. · prophylaxis of herpes simplex infections in immune-competent patients. · treatment of acute herpes zoster (shingles) infections, for the reduction of the duration and severity of acute symptoms and rash, for the reduction of all zoster associated pain and for the reduction of the incidence and duration of postherpetic neuralgia. · management of patients with severe aids who have a cd4 count of less than 50/µl. studies have shown that oral aciclovir given in conjunction with antiretroviral therapy reduced mortality in patients with advanced hiv disease. · patients undergoing allogenic bone marrow transplantation who are at risk of developing cmv infection while immunosuppressed (preceded by one month's treatment with intravenous aciclovir). studies have shown that oral aciclovir reduced mortality in allogenic bone marrow transplant recipients. in addition oral aciclovir provided effective prophylaxis for herpes virus disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - tetrabenazine 25mg - tablet - 25 mg - active: tetrabenazine 25mg excipient: iron oxide yellow lactose monohydrate magnesium stearate pregelatinised maize starch purified talc - tetrabenazine is indicated for the treatment of moderate to severe tardive dyskinesia, which is disabling and/or socially embarrassing. the condition should be persistent despite withdrawal of antipsychotic therapy, or in cases where withdrawal of antipsychotic medication is not a realistic option; also where the condition persists despite reduction in dosage of antipsychotic medication or switching to atypical antipsychotic medication.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - indapamide hemihydrate 2.5mg - tablet - 2.5 mg - active: indapamide hemihydrate 2.5mg excipient: hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry pink oy-6925 sodium laurilsulfate

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - naproxen 250mg;  ;   - tablet - 250 mg - active: naproxen 250mg     excipient: lactose monohydrate magnesium stearate maize starch povidone quinoline yellow sodium starch glycolate sunset yellow fcf

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - naproxen 500mg;  ;   - tablet - 500 mg - active: naproxen 500mg     excipient: lactose monohydrate magnesium stearate maize starch povidone quinoline yellow sodium starch glycolate sunset yellow fcf